Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MELANOMA DRUG RESIST

Financiado

Cerrado

Identification of drug resistance genes for the development of effective combine...

Identification of drug resistance genes for the development of effective combined therapies for melanoma Malignant melanoma is a highly aggressive form of skin cancer with a poor outcome following metastatic spread. Chemotherapies for metastatic melanoma are rarely curative because of the emergence of clones from within the tumor tha... ver más

30/06/2016

GRL

222K€

Presupuesto del proyecto: 222K€

Líder del proyecto

GENOME RESEARCH LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-06-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

GRL

0.00€ | Lider

Proyectos interesantes

ABC

Medical Technol...

Data Science

1M€ Cerrado

ZF-MEL-CHEMBIO

Medical Technol...

Data Science

2M€ Cerrado

RESICT-PC

Medical Technol...

Data Science

231K€ Cerrado

COMBAT-RES

Medical Technol...

Data Science

1M€ Cerrado

RTI2018-102204-B-I00

Medical Technol...

Data Science

375K€ Cerrado

EscaPI

Medical Technol...

Data Science

178K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

GENOME RESEARCH LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 222K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Malignant melanoma is a highly aggressive form of skin cancer with a poor outcome following metastatic spread. Chemotherapies for metastatic melanoma are rarely curative because of the emergence of clones from within the tumor that carry lesions in genes that confer therapeutic resistance. Understanding the genetic culprits of drug resistance will allow the rationale development of combination therapies that may circumvent the occurrence of resistance. Here I propose to combine different cutting-edge technologies and functional screenings in human early-passage melanoma cell cultures (EMCCs) to identify clinically relevant melanoma drug-resistance genes and consequently to develop new effective combination therapies by a data-driven approach. I will screen a library of drugs across a collection of EMCCs and in concert analyze the genome of each EMCC for mutations, epimutations and chromosomal aberrations. EMCCs found to be intrinsically resistant to a given drug will be screened with a short-hairpin-RNA library to identify genes whose knockdown reverts resistance. Those EMCCs sensitive to a given drug will be infected with lentiviral-vector based insertional mutagens to screen for genes whose upregulation mediates drug resistance, thus identifying mechanisms that may be associated with relapse in patients treated with these compounds. These 2 approaches will provide a collection of drug-resistance and -sensitivity genes that will be then validated in vitro, in vivo and in clinical samples. The knowledge of drug-resistance genes and genomic lesions carried by each EMCC will guide the design of new therapies based on the combination of multiple compounds targeting both the mutated gene and the EMCC-specific drug-resistance gene. The new combination regimens will be tested in vitro on EMCCs and in vivo in xenotransplant models. These results will pave the way to preclinical and clinical development of new combined therapies for the efficient eradication of melanoma.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores